NZ726050A - Modulators of androgen synthesis - Google Patents

Modulators of androgen synthesis

Info

Publication number
NZ726050A
NZ726050A NZ726050A NZ72605015A NZ726050A NZ 726050 A NZ726050 A NZ 726050A NZ 726050 A NZ726050 A NZ 726050A NZ 72605015 A NZ72605015 A NZ 72605015A NZ 726050 A NZ726050 A NZ 726050A
Authority
NZ
New Zealand
Prior art keywords
xazolepiperidine
benz
iso
modulators
androgen production
Prior art date
Application number
NZ726050A
Other languages
English (en)
Inventor
Gregory Alan Stoloff
Suzanne Jane Dilly
Paul Christopher Taylor
Original Assignee
Tangent Reprofiling Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangent Reprofiling Ltd filed Critical Tangent Reprofiling Ltd
Publication of NZ726050A publication Critical patent/NZ726050A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ726050A 2014-05-09 2015-05-11 Modulators of androgen synthesis NZ726050A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461990800P 2014-05-09 2014-05-09
PCT/EP2015/060388 WO2015169971A1 (en) 2014-05-09 2015-05-11 Modulators of androgen synthesis

Publications (1)

Publication Number Publication Date
NZ726050A true NZ726050A (en) 2018-04-27

Family

ID=53269444

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ726050A NZ726050A (en) 2014-05-09 2015-05-11 Modulators of androgen synthesis

Country Status (8)

Country Link
EP (1) EP3139923B1 (cg-RX-API-DMAC7.html)
JP (1) JP6730194B2 (cg-RX-API-DMAC7.html)
CN (1) CN106456644B (cg-RX-API-DMAC7.html)
AU (3) AU2015257594A1 (cg-RX-API-DMAC7.html)
CA (1) CA2950800C (cg-RX-API-DMAC7.html)
ES (1) ES2970762T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ726050A (cg-RX-API-DMAC7.html)
WO (1) WO2015169971A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2900270T3 (pl) 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis
CA3049980A1 (en) 2017-01-23 2018-07-26 Regeneron Pharmaceuticals, Inc. Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
CA3059348A1 (en) 2017-04-11 2018-10-18 Regeneron Pharmaceuticals, Inc. Assays for screening activity of modulators of members of the hydroxysteroid (17-beta) dehydrogenase (hsd17b) family
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
MY207352A (en) 2018-03-21 2025-02-21 Regeneron Pharma 17-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
MA56457A (fr) 2019-07-02 2022-05-11 Regeneron Pharma Modulateurs de hsd17b13 et leurs procédés d'utilisation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319950B1 (en) * 1997-02-18 2001-11-20 Michael C. Seidel Suppression of carcinoma using high purity conjugated linoleic acid (CLA)
CA2436536C (en) * 2000-12-23 2008-07-08 Creighton University Methods for inducing apoptosis and inhibiting proliferation in cancer cells
WO2004103262A2 (en) * 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
WO2012129673A1 (en) * 2011-03-25 2012-10-04 Universite Laval INHIBITORS OF 17ß-HSD1, 17ß-HSD3 AND 17ß-HSD10
PL2900270T3 (pl) * 2012-09-26 2019-09-30 Tangent Reprofiling Limited Połączenie benzo(izo)oksazolopiperydyn ze sprzężonym kwasem linolowym
US9375433B2 (en) * 2012-09-26 2016-06-28 Tangent Reprofiling Limited Modulators of androgen synthesis

Also Published As

Publication number Publication date
AU2015257594A1 (en) 2016-11-24
CA2950800C (en) 2023-01-10
AU2018203135A1 (en) 2018-05-24
ES2970762T3 (es) 2024-05-30
WO2015169971A1 (en) 2015-11-12
EP3139923A1 (en) 2017-03-15
AU2019279922A1 (en) 2020-01-16
CA2950800A1 (en) 2015-11-12
CN106456644B (zh) 2021-06-15
JP6730194B2 (ja) 2020-07-29
EP3139923B1 (en) 2023-09-27
CN106456644A (zh) 2017-02-22
JP2017514816A (ja) 2017-06-08

Similar Documents

Publication Publication Date Title
PH12017501999A1 (en) K-ras modulators
WO2014018563A3 (en) Methods for the treatment of cancer
EP3180010A4 (en) Combination therapy for treating cancer
MY198613A (en) Nitrobenzyl derivatives of anti-cancer agents
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
AU2014358850A8 (en) Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
AU2016256469A8 (en) Methods for treating cancer
EP3092006A4 (en) Targeted therapy for small cell lung cancer
EP3407978A4 (en) POLYTHERAPY FOR THE TREATMENT OF CANCER
TW201613648A (en) Compounds and compositions for immunotherapy
EP3399982A4 (en) ANTI-EGFR ASSOCIATIONS FOR THE TREATMENT OF TUMORS
EP4691562A3 (en) Anti-pd-l1 combinations for treating tumors
NZ732766A (en) Process for the preparation of a diarylthiohydantoin compound
EP3166640A4 (en) Combination therapy compositions and methods for treating cancers
WO2014164704A3 (en) Compounds and compositions for the treatment of cancer
PL2922828T3 (pl) Pochodne 4,6-diaminopirymidynowe jako inhibitory bmi-1 w leczeniu raka
EP3193884A4 (en) Combination therapy for treating cancer
EP3131552A4 (en) Methods for treating cancer using tor kinase inhibitor combination therapy
EP3207377A4 (en) Circulating tumor cell diagnostics for therapy targeting pd-l1
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2016009663A (es) Derivados de icariina.
PH12017501151A1 (en) Processes for the preparation of a diarylthiohydantoin compound
PH12017501879A1 (en) Methods for treating cancer
MX379622B (es) Compuestos espirociclicos
PH12015502757A1 (en) Combinations for the treatment of cancer comprising a mps-1 kinase inhibitor and a mitotic inhibitor

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2020 BY OLCOTT INTERANTIONAL

Effective date: 20190507

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2021 BY CPA GLOBAL

Effective date: 20200507

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2022 BY CPA GLOBAL

Effective date: 20210408

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2023 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20220502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2024 BY DENNEMEYER + CO

Effective date: 20230501

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2025 BY MS. MANDY LAUBACH

Effective date: 20240429

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 MAY 2026 BY DENNEMEYER + CO. SARL

Effective date: 20250428